Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”
Publication date: December 2026 Source: Journal of the American Academy of Dermatology, Volume 95, Issue 6 Author(s): Dina Ghanim, Michael Ghebrial, Chiara Tognaccini, Leah E. Thomas, Zahra Ansari, Khushi Gupta, Jashin J. Wu
Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226033037?dgcid=rss_sd_all
Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226033037?dgcid=rss_sd_all
“Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”.” Journal of the American Academy of Dermatology.
@article{article117212,
title = {Comment on Gao et al’s “A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis”},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226033037?dgcid=rss_sd_all}
}